What Makes Allergan an Attractive Target for Actavis?

The transcript discusses Actavis's interest in acquiring Allergan for over $60 billion, surpassing a hostile bid from Valeant backed by Bill Ackman. The deal is complex, with historical context involving multiple companies. Current negotiations have Actavis and Allergan close to an agreement, with Allergan opposing Valeant due to its reputation for cutting R&D. Financial challenges exist due to high valuations. Legal issues and investor reactions are also significant, with potential legal actions against Ackman for his stock accumulation methods.

What companies were mentioned as part of the acquisition talks involving Actavis?

Evaluate responses using AI:

OFF

What issues did the judge raise regarding Bill Ackman's accumulation of stock?

Evaluate responses using AI:

OFF